... Conference participants Systemic therapies established in the management of patients with neuroendocrine tumors (NETs) include somatostatin analogs and interferon-α, also referred to as biotherapy. Recent randomized controlled studies have extended the knowledge on the frequency of side effects associated...

... to somatostatin receptors varies according to the somatostatin analogues [ 27 ], and some patients who become resistant to one agent may on occasion respond to another. In addition, dose escalation and temporary treatment interruption, with institution of interferon-α, may help circumvent resistance [ 2...

...Heinz Gisslinger; Thomas Svoboda; Martin Clodi; Bettina Gilly; Heinz Ludwig; Liselotte Havelec; Anton Luger The successful therapeutic use of interferon-α (IFN-α) in myeloproliferative disorders offered the possibility to test its acute and long-term effects on the hypothalamic-pituitary-adrenal...

.... Angiogenesis Interferon-α Molecular neuroendocrinology Neuroendocrine tumors BON cells Mice Interferon (IFN)-α has been successfully used in the treatment of the neuroendocrine (NE) tumor patients. It has been shown to produce systematic response rates in 40–60% of patients, biochemical responses...

...Stefan Rosewicz; Katharina Detjen; Arne Scholz; Z. von Marschall In the current study, we investigated the effects of interferon-α (IFN-α) on proliferation and angiogenesis in neuroendocrine tumor disease. Using a panel of human neuroendocrine tumor cell lines, we confirmed functionally active IFN...